Asset Details
Do you wish to reserve the book?
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Do you wish to request the book?
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
2017
Overview
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development. Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents. The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending. As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment. Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells. We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.
Publisher
BMJ Publishing Group Ltd,BioMed Central,BioMed Central Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
Antineoplastic Agents, Immunological - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cancer
/ Colony-stimulating factors (Physiology)
/ CSF1
/ CSF1R
/ Dt-GCT
/ Humans
/ Kinases
/ Leukemia
/ Ligands
/ Lymphoma
/ Medicine
/ Melanoma
/ Oncology
/ PVNS
/ Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors
/ Review
/ Reviews
/ Tumors
